Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design

Peter Johannsen, Marie Bentsen, Kate Attfield, Kristian Steen Frederiksen, Giovanni B Frisoni, Rose Jeppesen, Ibrahim J Malik, Lotte Bjerre Knudsen · 2025

Read Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design by Peter Johannsen, Marie Bentsen, Kate Attfield, Kristian Steen Frederiksen, Giovanni B Frisoni, Rose Jeppesen, Ibrahim J Malik, Lotte Bjerre Knudsen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712370.txt.

Description

Peter Johannsen and seven co-authors set out the plan for a study of a diabetes drug in early Alzheimer's disease in a 2025 paper. The drug, semaglutide, acts on a gut hormone path that also touches brain swelling. Two large trials are already testing whether it slows early disease. This small study asks what it does to immune cells in blood and spinal fluid.

Twenty four people aged fifty five to seventy five with proven brain plaque will take the drug or a dummy in a blind trial. Single cell gene reads will track immune change in each arm. The authors lay out the grounds, the design, and the safety frame. Results should sharpen how the field reads the big trials.

Catalog record

CREATORPeter Johannsen, Marie Bentsen, Kate Attfield, Kristian Steen Frederiksen, Giovanni B Frisoni, Rose Jeppesen, Ibrahim J Malik, Lotte Bjerre Knudsen
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712370

Browse the full library · About the Tower of Babel